Suppr超能文献

肿瘤类器官和组装体:用于免疫治疗的患者来源癌症模型

Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.

作者信息

Mei Jie, Liu Xingjian, Tian Hui-Xiang, Chen Yixuan, Cao Yang, Zeng Jun, Liu Yung-Chiang, Chen Yaping, Gao Yang, Yin Ji-Ye, Wang Peng-Yuan

机构信息

Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.

出版信息

Clin Transl Med. 2024 Apr;14(4):e1656. doi: 10.1002/ctm2.1656.

Abstract

BACKGROUND

Organoid technology is an emerging and rapidly growing field that shows promise in studying organ development and screening therapeutic regimens. Although organoids have been proposed for a decade, concerns exist, including batch-to-batch variations, lack of the native microenvironment and clinical applicability.

MAIN BODY

The concept of organoids has derived patient-derived tumour organoids (PDTOs) for personalized drug screening and new drug discovery, mitigating the risks of medication misuse. The greater the similarity between the PDTOs and the primary tumours, the more influential the model will be. Recently, 'tumour assembloids' inspired by cell-coculture technology have attracted attention to complement the current PDTO technology. High-quality PDTOs must reassemble critical components, including multiple cell types, tumour matrix, paracrine factors, angiogenesis and microorganisms. This review begins with a brief overview of the history of organoids and PDTOs, followed by the current approaches for generating PDTOs and tumour assembloids. Personalized drug screening has been practised; however, it remains unclear whether PDTOs can predict immunotherapies, including immune drugs (e.g. immune checkpoint inhibitors) and immune cells (e.g. tumour-infiltrating lymphocyte, T cell receptor-engineered T cell and chimeric antigen receptor-T cell). PDTOs, as cancer avatars of the patients, can be expanded and stored to form a biobank.

CONCLUSION

Fundamental research and clinical trials are ongoing, and the intention is to use these models to replace animals. Pre-clinical immunotherapy screening using PDTOs will be beneficial to cancer patients.

KEY POINTS

The current PDTO models have not yet constructed key cellular and non-cellular components. PDTOs should be expandable and editable. PDTOs are promising preclinical models for immunotherapy unless mature PDTOs can be established. PDTO biobanks with consensual standards are urgently needed.

摘要

背景

类器官技术是一个新兴且发展迅速的领域,在研究器官发育和筛选治疗方案方面显示出前景。尽管类器官已被提出十年,但仍存在一些问题,包括批次间差异、缺乏天然微环境和临床适用性。

主体

类器官的概念已衍生出患者来源的肿瘤类器官(PDTO)用于个性化药物筛选和新药发现,降低了药物滥用的风险。PDTO与原发性肿瘤的相似性越高,该模型的影响力就越大。最近,受细胞共培养技术启发的“肿瘤组装体”引起了关注,以补充当前的PDTO技术。高质量的PDTO必须重新组装关键成分,包括多种细胞类型、肿瘤基质、旁分泌因子、血管生成和微生物。本综述首先简要概述类器官和PDTO的历史,然后介绍当前生成PDTO和肿瘤组装体的方法。个性化药物筛选已经在实践中;然而,PDTO是否能够预测免疫疗法,包括免疫药物(如免疫检查点抑制剂)和免疫细胞(如肿瘤浸润淋巴细胞、T细胞受体工程化T细胞和嵌合抗原受体T细胞)仍不清楚。PDTO作为患者的癌症替身,可以扩增和储存以形成生物样本库。

结论

基础研究和临床试验正在进行中,目的是使用这些模型替代动物。使用PDTO进行临床前免疫疗法筛选将对癌症患者有益。

关键点

当前的PDTO模型尚未构建关键的细胞和非细胞成分。PDTO应该是可扩增和可编辑的。除非能够建立成熟的PDTO,否则PDTO是有前途的免疫疗法临床前模型。迫切需要具有共识标准的PDTO生物样本库。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39c6/11045561/094cdb774ded/CTM2-14-e1656-g004.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验